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A recent BMJ clinical review provided a useful and timely update on smoking cessation 1 We 
thought it would be useful to expand on the section of the review on ‘Who smokes’ by 
sharing the latest findings on smoking prevalence in England from a large national 
surveillance study which has been tracking smoking prevalence since 2006.2 Each month a 
new sample of approximately 1800 individuals aged ≥ 16 are selected using a form of 
random location sampling and complete a computer-assisted household survey with a trained 
interviewer. Prevalence data are weighted to match English census data on age, sex, and 
socioeconomic group. The methods have been shown to result in a sample that is nationally 
representative in its socio-demographic composition and proportion of smokers as compared 
with other large national surveys such as Health Survey for England.2 An advantage of the 
Smoking Toolkit Study is that the data are available within weeks of collection and published 
online at www.smokinginengland.info. 
 
For the first time in probably 80 years, England has seen smoking prevalence fall below 20%. 
In 2013, 22,167 adults were surveyed. The prevalence of cigarette smoking was 19.3% 
(95%CI 18.8 to 19.8). Smoking was rare at the start of the 20th century but increased 
relentlessly until the publication of ‘Smoking and Health’ in 1962 by which stage over 70% 
of men and 40% of women smoked.3  
 
The decline in prevalence started in the 1970s and since then has averaged 0.6% per year; in 
2013 it was slightly above this at 0.8% (www.smokinginengland.info). There is much still to 
be done, particularly on the social gradient in smoking, which contributes substantially to 
health inequalities.4 However, we hope that breaking the 20% barrier will motivate smoking 
cessation efforts across the country, including making more use of our stop-smoking 
services.5 
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